Small-Molecule Degraders beyond PROTACs—Challenges and Opportunities. (April 2021)
- Record Type:
- Journal Article
- Title:
- Small-Molecule Degraders beyond PROTACs—Challenges and Opportunities. (April 2021)
- Main Title:
- Small-Molecule Degraders beyond PROTACs—Challenges and Opportunities
- Authors:
- Kastl, Johanna M.
Davies, Gareth
Godsman, Eleanor
Holdgate, Geoffrey A. - Abstract:
- Targeted protein degradation (TPD) is a recent strategy, utilizing the cell's proteostasis machinery to deplete specific proteins. This represents a paradigm shift in early drug discovery, away from occupancy-driven to event-driven mechanisms. Recent efforts have focused on the development of proteolysis-targeting chimeras (PROTACs). These heterobifunctional molecules combine a target-specific binding moiety linked to an E3 ligase ligand and trigger selective ubiquitination of the target protein, marking it for proteasomal degradation. While these molecules can be highly efficacious, they generally have unfavorable physicochemical properties due to their large size. In contrast, smaller molecules that induce degradation could represent an attractive, simple option to overcoming the limitations of both traditional modulators and PROTACs. These molecules may have a range of mechanisms: recruitment of an E3 ligase (molecular glues), introduction of hydrophobic areas, or inducing local unfolding, each of which triggers degradation. We recently completed a high-throughput screen of 111, 000 compounds in a cellular HiBiT assay in an effort to identify such molecules. Preliminary analysis indicates that we have been able to identify alternative small-molecule degraders. We highlight methods for triage, characterization, selectivity, and mode of action. In summary, we believe that these types of small-molecule degraders, which may possibly have more acceptable physicochemicalTargeted protein degradation (TPD) is a recent strategy, utilizing the cell's proteostasis machinery to deplete specific proteins. This represents a paradigm shift in early drug discovery, away from occupancy-driven to event-driven mechanisms. Recent efforts have focused on the development of proteolysis-targeting chimeras (PROTACs). These heterobifunctional molecules combine a target-specific binding moiety linked to an E3 ligase ligand and trigger selective ubiquitination of the target protein, marking it for proteasomal degradation. While these molecules can be highly efficacious, they generally have unfavorable physicochemical properties due to their large size. In contrast, smaller molecules that induce degradation could represent an attractive, simple option to overcoming the limitations of both traditional modulators and PROTACs. These molecules may have a range of mechanisms: recruitment of an E3 ligase (molecular glues), introduction of hydrophobic areas, or inducing local unfolding, each of which triggers degradation. We recently completed a high-throughput screen of 111, 000 compounds in a cellular HiBiT assay in an effort to identify such molecules. Preliminary analysis indicates that we have been able to identify alternative small-molecule degraders. We highlight methods for triage, characterization, selectivity, and mode of action. In summary, we believe that these types of small-molecule degraders, which may possibly have more acceptable physicochemical properties than the inherently larger heterobifunctional molecules, are an exciting approach for inducing TPD, and we illustrate that a general screening approach can be successful in identifying useful start points for developing such molecules. … (more)
- Is Part Of:
- SLAS discovery. Volume 26:Number 4(2021)
- Journal:
- SLAS discovery
- Issue:
- Volume 26:Number 4(2021)
- Issue Display:
- Volume 26, Issue 4 (2021)
- Year:
- 2021
- Volume:
- 26
- Issue:
- 4
- Issue Sort Value:
- 2021-0026-0004-0000
- Page Start:
- 524
- Page End:
- 533
- Publication Date:
- 2021-04
- Subjects:
- targeted degradation -- PROTAC -- high-throughput screening -- cell-based screening -- molecular glues
Drugs -- Analysis -- Periodicals
Drugs -- Testing -- Periodicals
Biomolecules -- Analysis -- Periodicals
Biomolecules -- Analysis
Drugs -- Analysis
Drugs -- Testing
Drug Evaluation, Preclinical
Molecular Biology -- methods
Periodicals
Periodicals
615.1 - Journal URLs:
- http://journals.sagepub.com/home/jbx ↗
https://www.sciencedirect.com/journal/slas-discovery/ ↗
http://www.sagepublications.com/ ↗
https://www.journals.elsevier.com/slas-discovery ↗ - DOI:
- 10.1177/2472555221991104 ↗
- Languages:
- English
- ISSNs:
- 2472-5552
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15300.xml